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Omega-3 polyunsaturated fatty acids
17-Oxo-DHA
A B S T R A C T
Recently, growing attention has been given to new classes of bioactive lipid mediators derived from ω-3 poly-
unsaturated fatty acids, such as docosahexaenoic acid (DHA), especially in the context of their role as en-
dogenous signal modulators. One such molecule is 17-oxo-DHA, generated from DHA by the action of COX2 and
a dehydrogenase. The redox-sensitive transcription factor, Nrf2 plays a key role in cellular stress responses. In
the present study, the effects of 17-oxo-DHA on Nrf2-mediated expression of cytoprotective enzymes were ex-
amined in mouse skin in vivo and cultured murine epidermal JB6 cells. Topical application of 17-oxo-DHA
markedly elevated the nuclear localization of Nrf2 and expression of heme oxygenase-1 (HO-1) and NAD(P)
H:quinone oxidoreductase-1 in hairless mouse skin. In contrast to 17-oxo-DHA, the non-electrophilic metabolic
precursor 17-hydroxy-DHA was a much weaker inducer of Nrf2 activation and its target protein expression.
Likewise, 17-oxo-DHA significantly enhanced nuclear translocation and transcriptional activity of Nrf2 with
concomitant upregulation of HO-1 expression in cultured JB6 cells. 17-Oxo-DHA was a much stronger inducer of
Nrf2-mediated antioxidant response than its parent molecule, DHA. HO-1 expression was abolished in Nrf2
knockdown JB6 cells or embryo fibroblasts from Nrf2 knock out mice. 17-Oxo-DHA also markedly reduced the
level of Keap1 protein by inducing ubiquitination. Mutation of Cys151 and Cys273 in Keap1 abrogated 17-oxo-
DHA-induced ubiquitination and proteasome-mediated degradation of Keap1 as well as HO-1 expression, sug-
gesting that these cysteine residues are putative sites for 17-oxo-DHA binding. Further, Keap1 degradation sti-
mulated by 17-oxo-DHA coincided with accumulation of the autophagy substrate, p62/SQSTM1.
1. Introduction
Skin is constantly exposed to solar ultraviolet (UV) radiation and
other external oxidative stress stimuli, which generate reactive oxygen
species (ROS) [1]. The loss of redox homeostasis as a consequence of
excessive intracellular accumulation of ROS and/or reduced capacity of
antioxidant defence contributes to pathogenesis of skin carcinogenesis
and dermatitis as well as skin aging [2–4]. When cellular anti-oxidant
defense capacity is overwhelmed by ROS, the self-correcting adaptive
physiological response reestablishes homeostasis by inducing a cyto-
protective program [5]. A significant attention has been given to the
wide array of natural or synthetic agents that can prevent the harmful
effects of ROS by restoring normal redox homeostasis.
Cellular redox homeostasis is maintained by the constitutive in-
duction of genes that encode a distinct set of antioxidant and other
cytoprotective proteins [6]. These include heme oxygenase-1 (HO-1)
and NAD(P)H: quinoneoxidoreductase-1 (NQO1) that are involved in
cellular defense against oxidative stress [7]. Thus, HO-1 and NQO-1
knockout mice were more prone to skin tumor development [8,9]. The
robust induction of aforementioned antioxidant proteins is known to be
mediated by a principle redox regulator, nuclear factor erythroid 2-
related factor 2 (Nrf2) [10,11].
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Under unstressed conditions, Nrf2 is sequestered in the cytoplasm as
an inactive complex with Kelch-like ECH-associated protein 1 (Keap1)
[12,13]. By interacting with Nrf2, Keap1 enhances degradation of Nrf2
with the help of Cul3 ubiquitin ligase complex [14–16]. Cul3-mediated
ubiquitination is switched from Nrf2 to Keap1 in response to an oxi-
dative or electrophilic stimulus, which facilitates the subsequent de-
gradation of Keap1 [17,18]. As a result, a Keap1-Nrf2 complex is dis-
rupted, and the Keap1-directed Nrf2 degradation is impeded. Once
dissociated from Keap1, Nrf2 translocates into the nucleus where it
binds to antioxidant response element (ARE) or electrophile response
element (EpRE) to drive the transcription of many antioxidant and re-
lated stress-responsive genes [10,19].
Health beneficial effects of long chain omega-3 polyunsaturated
fatty acids (n-3 PUFAs) have been corroborated by results from various
laboratory, population-based and clinical studies [20–22]. n-3 PUFAs
possess anti-oxidative and anti-inflammatory properties [23–25]. A
representative n-3 PUFA abundant in the fish oil is docosahexaenoic
acid (DHA). Results from previous studies clearly demonstrate that
dietary supplementation of DHA alleviates symptoms of diverse pa-
thological conditions linked to oxidative stress and inflammation
[26,27].
Groeger et al. have identified a new class of n-3 electrophilic fatty
acid oxo-derivatives (EFOXs) that are generated in activated macro-
phages, neutrophils and some animal tissues, underscoring their po-
tential as bioactive lipid mediators capable of modulating several cel-
lular signaling pathways including Nrf2-dependent anti-oxidant
response [28]. The formation of these reactive species was dependent
on cyclooxygenase-2 (COX-2), especially in the presence of aspirin. In
this study, we have focused on 17-oxo-DHA, a mono-oxygenated elec-
trophilic metabolite of DHA. Owing to endogenous nature together with
its potential to simultaneously stimulate multiple cytoprotective path-
ways [29–31], 17-oxo-DHA may contribute, at least in part, to the
protective effects of DHA against oxidative stress as well as inflamma-
tion-associated disorders. In this study, we examined whether 17-oxo-
DHA could exert anti-oxidative effects by activating the Nrf2 and sub-
sequently upregulating expression of its target proteins in mouse skin in
vivo and cultured mouse skin epidermal cells.
2. Methods
2.1. Chemicals and reagents
DHA (purity> 98%), 17-oxo-DHA (17-keto-4(Z),7(Z),10(Z),13(Z),
15(E),19(Z)-docosahexaenoic acid), and 17-hydroxy-DHA (17-hydroxy-
4Z,7Z,10Z,13Z,13Z,15E,19Z-docosahexaenoic acid) were supplied by
Cayman Chemical Co. (Ann Arbor, MI, USA). Primary antibodies for
Nrf2 and Keap1 were purchased from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA, USA). Rabbit polyclonal HO-1 antibody was a product
of Abcam (Cambridge, UK) or Stressgen (Ann Arbor, MI, USA).
Antibody for NQO-1 was procured from Abcam (Cambridge, UK) and
Enzo Life Sciences (Farmingdale, NY, USA). Primary antibodies for
lamin B and α-tubulin were the product of Santa Cruz Biotechnology,
Inc. (Santa Cruz, CA, USA). Anti-rabbit and anti-mouse horseradish
peroxidase-conjugated secondary antibodies were obtained from Pierce
Biotechnology (Rockford, IL, USA). The bicinchoninic acid (BCA) pro-
tein assay reagent was supplied by Pierce Biotechnology (Rockford, IL,
USA). Antibody for β-actin was provided by Santa Cruz Biotechnology,
Inc. (Santa Cruz, CA, USA). Polyvinylidene difluoride (PVDF) mem-
brane was obtained from Gelman Laboratory (Ann Arbor, MI, USA).
The enhanced chemiluminescent detection reagent was purchased from
Amersham Pharmacia Biotech (Arlington Heights, IL, USA). Eagle's
Minimum Essential Media (MEM), fetal bovine serum (FBS) were ob-
tained from Gibco BRL (Grand Island, NY, USA). The Nrf2 siRNA (
5′-UUCUGUCGCUGACUAAAGUCAAACA-3′) and Stealth™ universal
RNAi negative control duplexes were purchased from Invitrogen
(Carlsbad, CA, USA). The plasmid pH015-luc was kindly provided by
Dr. J. Alam from Alton Ochsner Medical Foundation (New Orleans, LA,
USA).
2.2. Animal treatment
Female HR-1 hairless mice (5–6 weeks of age) were purchased from
Sankyo Labo Service Corporation, Inc. (Tokyo, Japan). Animals were
kept in climate-controlled quarters (24 °C at 50% humidity) with a 12-h
light/12-h dark cycle. DHA (10 μmol), 17-oxo-DHA (20 nmol), and 17-
OH-DHA (20 nmol) were dissolved in 200 μl of acetone. These com-
pounds were topically applied onto the dorsal skin of mice for 2.5 or
5 h. Control animals were treated with the vehicle only.
2.3. Cell culture and transient transfection
Mouse epidermal JB6 Cl 41 cells were obtained from the American
Type Culture Collection (Manassas, VA, USA) and were cultured in
monolayers at 37 °C, 5% CO2 by using MEM, containing 5% FBS,
1.5 mg/ml sodium bicarbonate. Cells at a confluence of 60–70% were
transfected with control siRNA or Nrf2 siRNA (25 nM) with lipofecta-
mine RNAi-MAX reagent according to the manufacturer's instructions.
After 36 h transfection, cells were treated with DHA for additional 12 h,
and cell lysates were prepared as described earlier.
2.4. Reverse transcrption polymerase chain reaction (RT-PCR)
Total RNA was isolated from the skin tissue or JB6 Cl 41 cells by
using TRIzol® (Invitrogen; Carlsbad, CA, USA) according to the protocol
supplied by the manufacturer. To generate cDNA, 1 μg of total RNA was
reverse transcribed with murine leukemia virus reverse transcriptase
(Promega; Madison, WI, USA) for 50min at 42 °C and again for
15min at 72 °C. One μl of cDNA was amplified in sequential reactions
using Maxtime PCR PreMix Kit (iNtRON Biotechnology). For in vivo
experiment with mouse skin, the mRNA expression of actin (40 cycle of
94 °C for 30 s, 49 °C for 35 s, and 72 °C for 30 s), nrf2 (40 cycles of 94 °C
for 15 s, 51 °C for 15 s, and 72 °C for 30 s), and keap1 (35 cycles of 94 °C
for 30 s, 55 °C for 30 s, and 72 °C for 30 s) was checked. For cell culture
studies, the mRNA expression of nrf2 (25 cycles of 94 °C for 30 s, 55 °C
for 30 s, and 72 °C for 30 s), keap1 (23 cycles of 94 °C for 30 s, 55 °C for
30 s, and 72 °C for 30 s), ho-1 (20 cycles of 94 °C for 30 s, 53 °C for 35 s,
and 72 °C for 30 s) and actin (20 cycles of 94 °C for 30 s, 59 °C for 35 s,
and 72 °C for 30 s) was examined.
After that, a final extension was performed for 7min at 72 °C. The
primers used for RT-PCR reactions are as follows (forward and reverse,
respectively): nrf2, 5′-CTT TAG TCA GCG ACA GAA GGA C-3′ and 5′-
AGG CAT CTT GTT TGG GAA TGT G-3′; keap1, 5′-GGC AGG ACC AGT
TGA ACA GT-3′ and 5′-GGG TCA CCT CAC TCC AGG TA-3′; ho-1, 5′-
TAC ACA TCC AAG CCG AGA AT-3′ and 5′-GTT CCT CTG TCA GCA TCA
CC-3’; p62, 5'-CAG CTG TTT CGT CCG TAC CT-3' and 5'-AAA AGG CAA
CCA AGT CCC CA-3'; actin, 5′-AGA GCA TAG CCC TCG TAG AT-3′ and
5′-CCC AGA GCA AGA GAG GTA TC-3′ (forward and reverse, respec-
tively). Amplified products were resolved by 2% agarose gel electro-
phoresis, followed by staining with SYBR® green, and then photo-
graphed using fluorescence in LAS-4000.
2.5. Western blot analysis
For the preparation of the mouse epidermal protein extract, fat and
dermis taken off from the harvested skin samples were kept on ice, and
the fat-free epidermis was immediately placed in liquid nitrogen. The
pulverized skin was homogenized on ice with a Polytron® tissue
homogenizer and lysed in 1ml ice-cold lysis buffer. Lysates were cen-
trifuged twice at 14,000 × g for 30min and 15min. The supernatant
was collected, and total protein concentration was quantified by using
the BCA protein assay kit. Cell lysates (30 μg protein) were mixed with
sodium dodecyl sulfate (SDS) sample loading dye and boiled for 5min
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before electrophoresis on 8–15% SDS-polyacrylamide gel. After trans-
ferring to PVDF membrane, the blots were blocked with 3% fat-free dry
milk-TBST (Tris-buffer saline containing 0.1% Tween 20) for 1 h at
room temperature and then washed with the TBST buffer. The mem-
branes were incubated for 4 h at room temperature with primary anti-
bodies for HO-1 and overnight at 4 °C with primary antibodies for Nrf2,
Keap1, NQO-1, actin, α-tubulin, and lamin B. Blots were washed three
times with TBST at 10min intervals followed by incubation with
1:3000 dilution of respective horseradish peroxidase conjugated sec-
ondary antibodies (rabbit, goat or mouse) for 2 h at room temperature.
After blots were rinsed again three times with TBST, the immunoblots
were visualized with an ECL detection kit according to the instructions
provided in the protocol and visualized afterward.
2.6. Preparation of cytosolic and nuclear extracts
For homogenizing dorsal skin tissues of mice, 1ml of buffer A
[1mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES);
2 mM KCl; 1mM MgCl2; 0.1 mM dithiothreitol (DTT); 0.1mM EDTA;
0.1 mM phenylmethylsulfonylfluoride (PMSF)] was added. The
homogenates were then centrifuged for 15min at 18,000×g; The su-
pernatant was collected as cytosolic fraction and stored at −70 °C. The
precipitated nuclei were washed once with 200 μl of buffer A plus 2 μl
of 10% NP-40, centrifuged, resuspended in 200 μl of buffer C [1mM
HEPES, 5mM NaCl, 0.1 mM EDTA, 0.1mM DTT, 0.1mM PMSF, 100%
glycerol], and subsequently centrifuged for 15min at 21,000×g. The
supernatant containing nuclear extract was collected and stored at
−70 °C. Finally, the concentrations of protein were checked in both
cytosolic and nuclear fractions.
For the preparation of JB6 cell lysates, treated cells were gently
washed with cold phosphate buffered saline (PBS), scraped and cen-
trifuged at 4000 rpm for 5min. Pellets were suspended in 1x cell lysis
buffer enriched with protease inhibitor and incubated on ice for 1 h
followed by centrifugation at 14,000×g for 15min. Supernatant was
collected as whole cell lysate. For making cytosolic and nuclear ex-
tracts, cell pellets were suspended in cold hypotonic buffer A [10mM
HEPES (pH 7.9), 10mM KCl, 0.3mM EDTA, 0.2mM DTT, 0.1 mM
PMSF], incubated for 10min on ice and then centrifuged at 6,000×g
for 5min at 4 °C. Supernatant was collected as cytosolic extract. The
residual pellets were washed with hypotonic buffer and resuspended in
Fig. 1. Effects of DHA on the expression of Nrf2,
Keap1 and its target proteins in mouse skin in vivo.
Dorsal skin of female HR-1 hairless mice (n=3 per
group) was treated topically with 10 μmol of DHA.
(A, B) After 2.5 h of DHA treatment, the protein le-
vels of Nrf2 (A) and Keap1 (B) in the epidermal
tissue lysates were measured by Western blot ana-
lysis as described in Methods. (C) After DHA treat-
ment for 2.5 h, RT-PCR analysis was performed to
measure mRNA expression of nrf2, keap1, and actin.
(D) The expression of Nrf2 target proteins, HO-1 and
NQO-1, was also measured by Western blot analysis
after 4-h DHA application. Data are means ± SE.
**p < 0.01 and ***p < 0.001. (E) 17-Oxo-DHA, an
electrophilic derivative of DHA, is generated by
COX-2 catalyzed mechanism in activated macro-
phages. Modulation of COX-2 activity by aspirin
increases the rate of electrophilic metabolite pro-
duction.
M.U. Jamil, et al. Archives of Biochemistry and Biophysics 679 (2020) 108156
3
hypertonic buffer C [20mM HEPES (pH 7.8), 25% glycerol, 400mM
NaCl, 1 mM EDTA, 1mM DTT, 0.5mM PMSF], keeping on ice for
30min during rocking followed by centrifugation at 14,000×g for
5min. The supernatant containing nuclear proteins was collected and
stored at −70 °C. Protein concentration of whole cell lysate and cyto-
solic extracts were determined by using BCA protein assay kit. Protein
samples from whole cell lysate, cytosolic extract or nuclear fraction
were mixed with SDS sample loading dye and boiled for 5min. Proteins
were electrophoresed on SDS-polyacrylamide gel and transferred to
PVDF membranes. The blots were then blocked with 5% fat-free dry
milk-TBST buffer for 1 h at room temperature. The blots were incubated
with primary antibodies in 3% fat-free dry milk-TBST. Following three
washes with TBST, the blots were incubated with horseradish perox-
idase-conjugated secondary antibodies in 3% fat-free dry milk-TBST for
1 h at room temperature. The blots were rinsed again three times with
TBST, and the transferred proteins were incubated with the ECL sub-
strate detection reagent for 1min according to the manufacturer's in-
structions and visualized with X-ray film in the dark room.
2.7. Immunofluorescence staining of mouse skin
Using 10% paraformaldehyde, skin tissues were fixed at room
temperature. Following the permeabilization with 0.2% Triton, they
were blocked with 3% bovine serum albumin (BSA) in PBS for 1 h. The
tissues were then incubated with HO-1 primary antibody overnight.
Alexa Fluor® conjugated secondary antibodies were used prior to
mounting with 4′,6-diamidino-2-phenylindole (DAPI) for the purpose of
nuclear staining.
2.8. HO-1 promoter luciferase reporter gene assay
JB6 Cl 41 cells were transfected at a confluence of 50% in 12-well
plate with pHO15luc vector (0.75 μg) using Lipofectamine™ LTX for
24 h. After transfection, cells were treated with 17-oxo-DHA or DHA for
additional 12 h, and cell lysate was prepared by using 1x luciferase
reporter lysis buffer (Promega, Madison, WI, USA). After incubating cell
lysates with a luciferase substrate, the luciferase activity was measured
Fig. 2. Effects of 17-oxo-DHA on the Nrf2/Keap1
signaling and target protein expression in mouse
skin. Dorsal skin of female HR-1 hairless mice
(n=3 per group) was treated topically with 17-oxo-
DHA (20 nmol) for 2.5 h (A, B) and 5 h (C, D, E). (A,
B) After 2.5 h of 17-oxo-DHA treatment, the nuclear
Nrf2 (A) and cytosolic Keap1 (B) levels were as-
sessed by Western blot analysis. (C) After 5 h of 17-
oxo-DHA treatment, the mRNA expression levels of
nrf2 and keap1 were examined by RT-PCR analysis.
(D) The expression of Nrf2 and its target protein,
HO-1 in the whole skin tissue lysates was measured
by Western blot analysis. (E) Induction of HO-1
expression was further verified by immuno-
fluorescence analysis. Data are means ± SE.
**p < 0.01.
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by the luminometer. The β-galactosidase assay was conducted ac-
cording to the supplier's instructions for normalizing the luciferase ac-
tivity. The relative luciferase activity was obtained by normalizing lu-
ciferase activity against β-galactosidase activity.
2.9. Immunocytochemical analysis
JB6 Cl41 cells were plated on the 8-well chamber slide and treated
with 17-oxo-DHA or DHA. Cells were fixed in 95% methanol/5% dis-
tilled water for 10min at −20 °C. After rinsing with PBST, cells were
blocked for 1 h at 4 °C with fresh blocking buffer (0.1% Tween 20 in
PBS, pH 7.4, containing 5% BSA) and probed with primary antibody for
Nrf2 at 1:100 dilution in 5% BSA in PBST buffer overnight at 4 °C. After
three washes with PBST, cells were incubated with fluorescein iso-
thiocyanate (FITC)-goat-antimouse secondary antibody in PBST with
5% BSA for 1 h at room temperature. Cells were rinsed with PBST, and
stained cells were analyzed under fluorescence microscope.
2.10. Molecular docking simulation of interaction between 17-oxo-DHA
and Keap1
Covalent docking simulation was performed to predict binding pose
of 17-oxo-DHA with selected reactive cysteine residues in position of
mouse Keap1 protein using a CovDock module implemented in the
Schrodinger program (Schrodinger, L.L.C., NY, USA). A putative mouse
Keap1 structure was constructed based on human Keap1 BTB domain
(PDB ID: 4CXI) and human KLKL11 BTB and BACK domains (PDB ID:
3I3N) as the BTB and IVR domains using a Prime module in the
Schrodinger program. Quality control analysis by the PROCHECK pro-
gram identified 92.3% residues of the model located in the most fa-
vorable regions of the Ramachandran plot.
Preparation of a protein structure was processed through “Protein
Preparation Wizard” in the Schrodinger program. The minimization
was terminated when the root mean square deviation of the heavy
atoms in the energy minimized structure relative to the starting co-
ordinates exceeded 0.3 Å using OPLS3e force field. The grid size for
covalent docking simulation was set to 15 Å in the centroid of the
Fig. 3. Comparative effects of 17-oxo-DHA and DHA on the nuclear translocation of Nrf2 and expression of HO-1 and NQO-1 in mouse skin. Dorsal skin of female HR-
1 hairless mice (n= 3 per group) was treated topically with 17-oxo-DHA (20 nmol) or DHA (10 μmol). (A) After 5 h of topical application, the protein levels of Nrf2
in the nuclear fraction were measured by Western blot analysis. (B) The expression of Nrf2-regulated cytoprotective proteins was determined in whole tissue lysates
by Western blot analysis. Data are means ± SE. *p < 0.05, **p < 0.01, and ***p < 0.001.
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cysteine 151 and 273. 17-Oxo-DHA was sketched and was minimized
with MMFFs force field through “LigPrep” in the Schrodinger program.
Flexible ligand sampling with the SP docking mode was considered in
the docking procedure. The predefined “Michael addition” reaction was
used to form covalent bonds. All other parameters were set to defaults
for the CovDock docking procedure.
2.11. Statistical analysis
Results were expressed as the mean ± SE or SD of at least three
independent experiments. In particular, statistical significance was
determined by Student's t-test, and the criterion for statistical sig-
nificance was p-value< 0.05.
3. Results
3.1. DHA elevates the expression of Nrf2 and its target proteins in mouse
skin in vivo
In order to determine the ability of DHA in stimulating the Nrf2-
dependent antioxidant response in mouse skin, we initially examined
the expression of a Nrf2 and its negative regulator, Keap1 in epidermal
tissue lysates by Western blot analysis. When shaven back of female
hairless C57BL/6 mice was treated topically with DHA (10 μmol) for
2.5 h, an elevated level of Nrf2 was observed compared to vehicle-
treated control skin (Fig. 1A). Under the same experimental conditions,
the protein expression of Keap1 was decreased (Fig. 1B). However, the
mRNA expression levels of nrf2 and keap1 did not change in response to
DHA treatment (Fig. 1C). Topical application of DHA also resulted in
enhanced expression of HO-1 and NQO-1, two representative target
proteins regulated by Nrf2, in mouse skin (Fig. 1D).
DHA undergoes oxidative metabolism to produce 17-oxo-DHA that
has an α,β-unsaturated carbonyl moiety (Fig. 1E). Topical application
of DHA onto hairless mice gave rise to the formation of 17-oxo-DHA as
well as 17-OH-DHA (Seonghoon Kim and Young-Joon Surh, un-
published observation). Due to its electrophilic nature, 17-oxo-DHA is
speculated to modulate intracellular redox signaling. Though this 17-
oxo-DHA has been shown to activate Nrf2 in cultured macrophages and
some epithelial cells [28,29], the in vivo effects of this EFFOX in ex-
perimental animals have not been reported yet. This prompted us to
assess its capability to activate Nrf2-mediated antioxidant response in
mouse skin in vivo.
Fig. 4. The comparative effects of 17-oxo-DHA and
its precursor 17-OH-DHA on Nrf2 nuclear accumu-
lation, Keap1 degradation, and expression of HO-1
and NQO-1 in mouse skin. (A) Chemical structures
of 17-oxo-DHA and its metabolic precursor 17-OH-
DHA. 17-Oxo-DHA harbours an α,β-unsaturated
carbonyl moiety that serves as an electrophile,
whereas 17-OH-DHA is non-electrophilic. (B) Dorsal
skin of female HR-1 hairless mice (n= 3 per group)
was treated topically with 17-oxo-DHA (20 nmol) or
17-OH-DHA (20 nmol). (B) After 5 h of treatment,
the protein levels of nuclear Nrf2 and cytosolic
Keap1 were determined by Western blot analysis.
(C) The expression of HO-1, and NQO-1 in the
whole tissue lysates was also measured by Western
blot analysis. Data are means ± SE. *p < 0.05 and
**p < 0.01.
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3.2. 17-Oxo-DHA increases nuclear translocation of Nrf2 while it decreases
the steady-state level of Keap1 in hairless mouse skin
After topical application of 17-oxo-DHA (20 nmol) onto the dorsal
skin of female HR-1 hairless mice, there were marked increases in nu-
clear accumulation of Nrf2 (Fig. 2A) with a concomitant decrease in the
cytoplasmic levels of Keap1 (Fig. 2B). Like DHA, 17-oxo-DHA did not
change the level of their mRNA transcripts when topically applied onto
mouse skin (Fig. 2C). These data suggest that 17-oxo-DHA stabilizes
Nrf2 protein, while stimulating the degradation of Keap1. The 17-oxo-
DHA treatment also induced HO-1 expression (Fig. 2D) which was
verified by immunofluorescence staining (Fig. 2E).
3.3. 17-Oxo-DHA induces nuclear translocation of Nrf2 and subsequent
expression of its target proteins to a greater extent than DHA
In the next experiment, we compared the capability of DHA and its
reactive metabolite, 17-oxo-DHA on Nrf2 activation and its target
protein expression in mouse skin. Notably, there was more pronounced
localization of Nrf2 in nucleus (Fig. 3A) and expression of HO-1 and
NQO-1 (Fig. 3B) induced by 17-oxo-DHA, even at a lower dose
(20 nmol), than that achieved with the parent compound, DHA
(10 μmol). Taken together, these results suggest that 17-oxo-DHA may
contribute, at least in part, to Nrf2-mediated anti-oxidative response
induced by topically applied DHA in mouse skin in vivo.
3.4. 17-OH-DHA, a non-electrophilic metabolic precursor of 17-oxo-DHA,
is a weaker activator of Nrf2-mediated antioxidant signaling
It is speculated that the electrophilic nature of 17-oxo-DHA confers
this metabolite the potential to trigger the Nrf2-mediated anti-oxidative
response in mouse skin. To test this supposition, the comparative effects
of 17-oxo-DHA and its non-electrophilic precursor, 17-OH-DHA
(Fig. 4A) on Nrf2-Keap1 signaling were examined. As shown in Fig. 4B,
17-oxo-DHA strongly induced nuclear translocation of Nrf2 and cyto-
plasmic degradation of Keap1, but 17-OH-DHA had little effects. Like-
wise, 17-OH-DHA was a much weaker inducer of the expression of HO-
1 and NQO-1 in mouse skin compared with 17-oxo-DHA (Fig. 4C).
Fig. 5. Comparative effect of 17-oxo-DHA and DHA
on nuclear translocation and transcriptional activity
of Nrf2 and HO-1 expression. (A) JB6 cells were
treated with 5 μM 17-oxo-DHA or 5 μM DHA and
harvested at the indicated times. Nuclear and cyto-
solic fractions were isolated as described in
Methods, and Nrf2 levels were assessed by Western
blot analysis. (B) JB6 cells were treated with 5 μM of
17-oxo-DHA or the same concentration of DHA for
3 h. After fixation, samples were incubated with
blocking agents, washed with PBST and then in-
cubated overnight with primary antibody. After
washing with PBS, samples were then incubated
with FITC-conjugated secondary antibody for 1 h.
Cells were also stained with propidium iodide (PI)
and examined under a fluorescent microscope. (C)
JB6 cells were transfected with the pH015-luc vector
for 24 h and were then treated with 5 μM 17-oxo-
DHA or 5 μM DHA for indicated time periods. The
cells were then lysed and analyzed for luciferase
activity. Data were expressed as means of± SD. (D)
JB6 cells were treated with 1, 10, 20 μM 17-oxo-
DHA or DHA for 24 h, and total proteins were iso-
lated and subjected to the Western blot analysis for
the measurement of HO-1 expression.
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3.5. 17-Oxo-DHA induces nuclear translocation of Nrf2 and Nrf2-mediated
HO-1 expression in cultured mouse epidermal cells
After confirming the activation of Nrf2-mediated antioxidant sig-
naling by DHA and 17-oxo-DHA in mouse skin in vivo, we attempted to
extend our findings to an in vitro model, using mouse epidermal JB6
cells. 17-Oxo-DHA (5 μM) treated to JB6 cells for 3 h increased the level
of Nrf2 in the nuclear fraction whereas the same concentration of DHA
barely induced nuclear accumulation of Nrf2 (Fig. 5A). 17-Oxo-DHA as
well as DHA at this concentration was not cytotoxic. The im-
munocytochemical analysis further demonstrates that 17-oxo-DHA is
more effective in inducing nuclear translocation of Nrf2 than DHA
(Fig. 5B). The Keap1 degradation was also more prominent in 17-oxo-
DHA-treated JB6 cells, compared with that in cells treated with DHA
(data not shown).
The promoter regions of HO-1 and many other antioxidant enzymes
harbour the consensus sequence, called ARE (or EpRE), a binding site
for Nrf2. To investigate the 17-oxo-DHA-induced transcriptional reg-
ulation of HO-1 by Nrf2, a promoter activity assay was conducted by
transfecting JB6 cells with an HO-1 promoter luciferase plasmid. As
illustrated in Fig. 5C, treatment with 5 μM 17-oxo-DHA increased the
luciferase activity, whereas the same concentration of DHA was not
effective. 17-Oxo-DHA also displayed a more potent effect on HO-1
protein expression than did DHA (Fig. 5D).
3.6. 17-Oxo-DHA stabilizes Nrf2 by decreasing the steady state level of
Keap1 in cultured JB6 cells
Nrf2 protein expression in JB6 cells was transiently up-regulated
upon treatment with 5 μM 17-oxo-DHA (Fig. 6A). In contrast to the
effects on Nrf2 protein expression, the same treatment failed to alter the
level of its mRNA transcript (Fig. 6B). The accumulated Nrf2 was pre-
dominantly localized in the nucleus (Fig. 6C). These results indicate
that 17-oxo-DHA regulates Nrf2 expression primarily at the post-tran-
scriptional level, rather than through de novo synthesis. The stability of
Nrf2 is mainly regulated by Keap1, which is a substrate adaptor protein
for Cul3-dependent E3 ubiquitin ligase complex. Thus, Keap1 represses
Nrf2 by targeting this transcription factor for ubiquitination and sub-
sequent proteasome-mediated degradation [14–16]. It has been re-
ported that ROS and electrophiles can cause switching of Cul3-depen-
dent ubiquitination of Nrf2 to Keap1, directing Keap1 to proteasomal
degradation [17,18]. As 17-oxo-DHA has an electrophilic moiety, it
may facilitate the Keap1 degradation through direct interaction. 17-
Oxo-DHA markedly decreased the steady-state level of Keap1 protein
Fig. 6. 17-Oxo-DHA-induced nuclear accumulation
of Nrf2 through Keap1 degradation in JB6 cells. (A,
B) JB6 cells were treated with 5 μM 17-oxo-DHA for
indicated time, and total protein and mRNA were
isolated for measurement of Nrf2 and Keap1 by
Western blot analysis (A) and RT-PCR (B), respec-
tively. (C) JB6 cells treated with 5 μM 17-oxo-DHA
were harvested at the indicated times. Nuclear and
cytosolic fractions were isolated, and Nrf2 levels
were analyzed by Western blot analysis. (D)
HEK293T cells were transfected with wild-type Flag-
Keap1 expression vector and treated with 5 μM of
17-oxo-DHA for indicated time periods. The levels of
exogenous keap1 mRNA were measured by RT-PCR.
(E) JB6 cells were treated with or without 17-oxo-
DHA and harvested after 6 or 12 h. Total protein was
then subjected to immunoprecipitation with Keap1
primary antibody followed by immunoblotting with
antibody against ubiquitin to visualize the ubiquiti-
nated Keap1.
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(Fig. 6D), corroborating the above supposition. However, its mRNA
level remained constant under the same experimental conditions
(Fig. 6E). Corroboratory results were also obtained with HEK 293T cells
transfected with an expression vector for wild-type Flag-Keap1,
whereby treatment with 17-oxo-DHA markedly reduced the steady-
state level of Keap1 (Fig. 6F). To determine whether Keap1 could be
ubiquitinated in response to 17-oxo-DHA treatment, JB6 cells were
treated with the compound for 6 h or 12 h, lysed and subjected to im-
munoprecipitation with Keap1 antibody followed by immunoblotting
with anti-ubiquitin antibody. As shown in Fig. 6G, 17-oxo-DHA mark-
edly increased Keap1 ubiquitination in JB6 cells.
3.7. Effects of Keap1 cysteine thiol modification by 17-oxo-DHA in its
activation of Nrf2-dependent transcription
Keap1 is a cysteine rich protein, with 27 cysteine residues in the
human and 25 in the murine protein. It has been reported that some
critical sensor cysteines of Keap1 can be oxidized by ROS or covalently
modified by electrophiles, leading to its conformational changes. This
disrupts the interaction between Keap1 and Nrf2, thereby preventing
degradation of newly synthesized Nrf2 [32]. As 17-oxo-DHA harbours
an α,β-unsaturated carbonyl moiety, it can serve as an electrophile
toward cellular nucleophiles, including cysteine thiols of Keap1. Several
studies have identified 3 critical cysteine residues, Cys151, 273, and
288, present in Keap1 as sensors for electrophiles and oxidants that are
speculated to be involved in regulating the activity of Nrf2 [32].
In order to determine which of these cysteine residues is/are in-
volved in the activation of Nrf2 following 17-oxo-DHA treatment, we
utilized expression vectors for Keap1 mutants in which each of afore-
mentioned 3 sensor cysteine residues was replaced by serine. HEK293T
cells transfected with expression vectors for wild-type, Keap1-C151S,
Keap1-C273S, or Keap1-C288S were treated with or without 17-oxo-
DHA, and the lysates were subjected to immunoblot analysis with an-
tibodies against Keap1 and HO-1. The Keap1 degradation and HO-1
induction observed in the wild-type cells were abrogated in cells har-
bouring Keap1 C151S or C273S mutation, but not in cells harbouring
C288S (Fig. 7A). Next, we attempted to find out whether these cysteine
residues are also involved in the 17-oxo-DHA-induced ubiquitination of
Keap1. As seen in Fig. 7B, a mutation at Cys151 or Cys273 abolished
ubiquitination of Keap1, suggesting that these cysteine residues are also
required for 17-oxo-DHA-induced proteasomal degradation of Keap1.
As an initial step toward determining whether Cys151 and Cys273
are putative sites for 17-oxo-DHA binding to Keap1, prediction of cova-
lent docking pose of 17-oxo-DHA the mouse Keap1 homology model was
performed. Cys151 is located at the tip of flexible loop in BTB domain,
while Cys273 is in the intervening region of IVR domain (Fig. 7C). In
Fig. 7. Effects of C151S, C273S, and C288S muta-
tion of Keap1 on 17-oxo-DHA mediated transacti-
vation of HO-1 expression. (A) HEK293T cells were
transfected with expression vectors for wild-type
Flag-Keap1 or mutant Keap1 for 24 h. Transfected
cells were treated with or without 17-oxo-DHA and
harvested at 6 h. Then, the expression levels of
Keap1 and HO-1 were determined by immunoblot
analysis. (B) Total protein was isolated, and Keap1
ubiquitination, and expression levels of Keap1 and
HO-1 were analyzed as described in the legend to
Fig. 6. (C) Covalent docking pose of 17-oxo-DHA in
BTB and IVR domains of mouse Keap1 protein. An in
silico docking model of Keap1 BTB and IVR domains
with three cysteine residues in the positions of 151,
273 and 288. (D, E) The ccovalent adduction be-
tween carbon 15 of 17-oxo-DHA and Cys151 (D)
and Cys273 (E) residues is shown. Gray carbon-
capped sticks represent the amino acids of Keap1.
Green dashed lines are hydrogen bonds.
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silico docking analysis reveals that the sulfur atom of both cysteine re-
sidues is likely to form a covalent bond with the electrophilic sp2 carbon
15 of 17-oxo-DHA through Michael addition. Carbonyl and carboxyl
groups of 17-oxo-DHA adducted to Cys151 were predicted to form hy-
drogen bonds with Lys150 and Arg135 residues, and a hydrophobic
chain is positioned at positively charged residues His129, Lys150 and
His154 (Fig. 7D). 17-Oxo-DHA covalently bound to Cys273 is predicted
to interact via a hydrogen bond with Arg269 at the narrow binding
pocket localized between helix bundles of the IVR domain (Fig. 7E).
3.8. 17-Oxo-DHA induces upregulation of HO-1 expression through Nrf2
activation
In parallel with accumulation of Nrf2, both transcription (Fig. 8A)
and translation (Fig. 8B) of HO-1 were elevated by 17-oxo-DHA in a
time-dependent manner. In a subsequent experiment, Nrf2 was silenced
by transfecting JB6 cells with siRNA, and the expression of HO-1 fol-
lowing 17-oxo-DHA treatment was measured by Western blot analysis.
As compared to cells transfected with scrambled siRNA, 17-oxo-DHA-
induced expression of HO-1 was abrogated in cells transfected with
siNrf2 (Fig. 8C), indicating that Nrf2 does mediate 17-oxo-DHA-in-
duced upregulation of HO-1 expression in mouse epidermal cells. Fur-
thermore, we utilized embryonic fibroblasts derived from Nrf2 wild-
type and knockout mice (MEFs) to further verify the role of Nrf2 in HO-
1 upregulation by 17-oxo-DHA. 17-Oxo-DHA induced the expression of
HO-1 in Nrf2 wild-type MEFs, while this was blunted in Nrf2 knockout
MEFs (Fig. 8D).
3.9. 17-Oxo-DHA induces degradation of Keap1 through p62-mediated
autophagy
Nrf2 is also regulated by p62 (also known as SQSMT1; sequesto-
some), the ubiquitin-binding protein that serves as an autophagy sub-
strate and a cargo receptor. Besides direct modification of Keap1 by
oxidants or electrophiles, its interaction with p62 promotes dissociation
of Nrf2 from Keap1 [33]. Based on our finding that 17-oxo-DHA induces
ubiquitination of Keap1, we tested the possible involvement of p62 in
degradation of ubiquitin-conjugated Keap1 following 17-oxo-DHA
treatment. We observed a time-dependent increase in p62 mRNA
(Fig. 9A) and p62 protein (Fig. 9B) levels upon 17-oxo-DHA treatment,
which coincided with the gradual decrease in the Keap1 protein level
(Fig. 6D). To further determine whether 17-oxo-DHA-induced de-
gradation of Keap1 is associated with p62-mediated autophagy, we
examined the Keap1 protein accumulation in JB6 cells treated with 17-
oxo-DHA in the presence of an autophagy inhibitor, bafilomycin. Ba-
filomycin restored the Keap1 protein level reduced by 17-oxo-DHA
(Fig. 9C).
4. Discussion
Nrf2 is a redox-sensitive master regulator of genes encoding many
cytoprotective enzymes required for cellular defence against oxidative
stress and other noxious conditions [10,11,34]. Among the enzymes
involved in Nrf2-mediated cellular stress response, HO-1 is of particular
interest because its expression is commonly induced by a wide array of
environmental and endogenous stressors. In various cells, the induction
of HO-1 confers protection against oxidative stress [35,36]. Dysfunction
of the aforementioned cytoprotective mechanism in the skin has been
associated with severe dermal stress and photocarcinogenesis [37,38].
In line with this notion, Nrf2 knockout mice were shown to be more
susceptible to chemically induced skin carcinogenesis [39].
A vast variety of anti-oxidative agents, many of which are con-
stituents of our daily diet, have been demonstrated to combat oxidative
skin damage and photocarcinogenesis [40]. Omega-3 polyunsaturated
fatty acids (n-3 PUFAs) abundant in fish oil have multiple health ben-
eficial effects, which are attributable to their anti-oxidative and anti-
inflammatory activities [23–27,41]. DHA, a representative n-3 PUFA,
modulates activities of redox-sensitive pro-inflammatory transcription
factors, such as NFκB [42,43] and STAT3 [44]. Our recent studies have
demonstrated that topically applied DHA inhibits UVB-induced
Fig. 8. Role of Nrf2 in 17-oxo-DHA induced upregulation of HO-1. (A, B) JB6
cells were treated with 5 μM 17-oxo-DHA for indicated time, and the expression
levels of HO-1 mRNA (A) and protein (B) levels were measured by RT-PCR and
Western blot analysis, respectively. (C) JB6 cells were transiently transfected
with 20 nM of si-Nrf2 for 24 h, and 17-oxo-DHA-induced HO-1 expression was
determined by Western blot analysis. (D) Nrf2-WT or Nrf2-Knockout MEF cells
were incubated with or without 5 μM 17-oxo-DHA and harvested after 6 h.
Total protein was isolated, and the HO-1 expression level was measured by
Western blot analysis.
Fig. 9. 17-Oxo-DHA-induced degradation of Keap1 through p62-mediated au-
tophagy. (A, B) JB6 cells were treated with 5 μM 17-oxo-DHA for indicated
time, and total mRNA (A) and protein (B) were isolated, and the p62 mRNA and
protein expression were measured by RT-PCR and Western blot analysis, re-
spectively. (C) Effects of an autophagy inhibitor, bafilomycin on Keap1 protein
accumulation in JB6 cells.
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carcinogenesis in mouse skin [44].
In view of the protective role of DHA in skin disorders often caused
by UV-induced oxidative tissue damage, we sought to first investigate
whether topical application of DHA could provoke anti-oxidative re-
sponse in mouse skin in vivo. We noticed that topically applied DHA
increased nuclear translocation of Nrf2, thereby upregulating anti-
oxidant enzyme expression. Recent studies have revealed the distinct
set of novel endogenous lipid mediators, generated from n-3 PUFAs
either enzymatically or through non-enzymatic oxidation reactions,
exert health beneficial effects. Among them, EFOXs are of principal
interest because of their potential to modulate broad range of signaling
molecules [28]. By forming reversible adducts with nucleophiles
through Michael addition, these electrophilic species modulate multiple
redox-sensitive signaling pathways including those mediated by Keap1/
Nrf2.
Electrophilic compounds bind Keap1 and disrupt proteasome-
mediated degradation of Nrf2. 17-Oxo-DHA that has an α,β-unsaturated
ketone moiety capable of directly binding Keap1 and activating Nrf2 in
cultured macrophages [28,29,45]. In our present study, 17-oxo-DHA
was found to be a more potent mediator than the non-electrophilic
precursor DHA in inducing the Nrf2-driven expression of cytoprotective
enzymes. Thus, 17-oxo-DHA, at a dose as low as 20 nmol, activated
Nrf2-mediated anti-oxidant signaling response to a greater extent than
DHA. 17-Oxo-DHA not only enhanced the steady-state level of Nrf2 at
post-translational levels, but also reduced the stability of Keap1 through
ubiquitin-proteasomal degradation. In contrast to 17-oxo-DHA, its non-
electrophilic metabolic precursor 17-OH-DHA induced much weaker
induction of Nrf2 activation and its target protein expression. 17-OH-
DHA may undergo oxidation to 17-oxo-DHA when topically treated to
mouse skin, possibly by epidermal dehydrogenase activity, and this
accounts for its marginal induction of Nrf2-HO-1 signaling.
Recently, extensive studies have been conducted to elucidate the
mechanism whereby cysteine modifications in Keap1 lead to Nrf2 ac-
tivation. Although there may exist several different possibilities of Nrf2
activation, the proposed mechanisms share one important perspective:
Keap1 is not just a repressor that sequesters Nrf2 in the cytoplasm, but
rather acts as an active mediator that targets Nrf2 for ubiquitination
and proteasomal degradation. Thus, Keap1 functions as a substrate
adaptor protein for the Cul3-dependent E3 ubiquitin ligase complex
[14–16]. Keap1 is rich in cysteine residues prone to be modified by
oxidants and electrophiles, and this hampers Keap1-directed ubiquiti-
nation of Nrf2 [32,46]. This prompted us to postulate that 17-oxo-DHA
may interact with particular cysteine residue(s) of Keap1 and thereby
causes its conformational changes, resulting in Nrf2 stabilization. The
site-directed mutation studies have identified 3 critical cysteine re-
sidues (Cys151, Cys273, and Cys288) of Keap 1 that are important
sensors for Nrf2 activators [32,46]. In particular, mutation of Cys151 to
serine has been shown to abolish electrophile- and oxidant-mediated
Nrf2 ubiquitination [46]. In line with this observation, our results in-
dicate that Cys151 is required for stabilization of Nrf2 in response to
17-oxo-DHA treatment. Two other cysteine residues, Cys273 and
Cys288 are required for Keap1 to repress Nrf2-dependent transcrip-
tional activation. However, 17-oxo-DHA-induced Keap1 degradation
was impaired in cells harbouring mutant Keap1-C273S, but not Keap1-
C288S. Based on these findings, we speculate that Cys151 and Cys273
may be putative binding sites of 17-oxo-DHA.
We suggest two possible mechanisms for 17-oxo-DHA-induced ac-
tivation of Nrf2 in murine epidermal JB6 cells as well as in mouse skin.
One is that 17-oxo-DHA modifies Cys151 of Keap1, and dissociation of
Keap1 from Cul3 abrogates Keap1 directed ubiquitination of Nrf2,
thereby activating Nrf2-dependent transcription of HO-1. Moreover, it
has been suggested that Cys273 may be required for binding of Keap1
to either E2 ubiquitin conjugating enzyme or E3 ubiquitin ligase com-
plex and that Cys273 may also be involved in ubiquitin transfer from E2
enzyme to Nrf2 [32]. On the basis of these findings and our results, we
suggest a second possible mechanism: 17-oxo-DHA modifies the Cys273
of Keap1, and thereby inhibiting Keap1-mediated ubiquitination of
Nrf2, resulting in Nrf2 stabilization. Though Cys151 and Cys273 have
been predicted to be potential sites to which 17-oxo-DHA binds, still
more direct evidence can be attained by mass-spectral analysis of di-
gested peptides derived from modified Keap1.
Still another plausible mechanism by which 17-oxo-DHA induces
Fig. 10. Schematic representation of Nrf2 activation and antioxidant gene expression by 17-oxo-DHA. 17-Oxo-DHA, an electrophilic oxo-derivative of DHA, harbours
an α,β-unsaturated carbonyl moiety, which is reactive towards cellular nucleophiles, such as cysteine residues of Keap1. Modification of specific thiol residues of
Keap1 leads to disruption of the Keap1-Nrf2 complex formation. This allows Nrf2 to translocate into the nucleus, where it binds to the ARE and activates transcription
of target genes (e.g., HO-1). Keap1 modification by 17-oxo-DHA also facilitates Keap1 degradation through p62-mediated autophagy.
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Nrf2 activation involves the autophagic degradation of its inhibitory
protein, Keap1. It has been reported that Keap1 ubiquitinated by a
Cul3-dependent complex undergoes proteasome-independent degrada-
tion [18]. p62, a scaffold protein, binds ubiquitin-positive cargos, and
targets them for degradation via autophage [47]. In agreement with
this notion, Keap1 degradation was found to be partly associated with
p62-mediated autophagy [33].
Several studies have suggested that p62 provokes the stabilization of
Nrf2 by directly interacting with Keap1, which results in disruption of
the Keap1-Nrf2 complex [33,48,49]. It has been demonstrated that
certain electrophiles accelerate the degradation of covalently modified
Keap1 by autophagy [50]. Likewise, it is conceivable that a con-
formational change of Keap1 induced by electrophilic 17-oxo-DHA may
facilitate p62-mediated autophagic degradation of Keap1 protein. How
structural modification of Keap1 by 17-oxo-DHA affects its interaction
with p62 for degradation via autophage merits further investigation.
Phosphorylation of p62 at specific serine residues enhances its affinity
for Keap1 as well as cargo protein. It'll be worthwhile determining
whether 17-oxo-DHA can promote phosphorylation of p62, thereby
facilitating the recruitment of Keap1 to the ubiquitinated cargo.
In conclusion, 17-oxo-DHA induces an Nrf2-mediated antioxidant
response in mouse skin in vivo and cultured murine epidermal cells,
which is attributable to its direct interaction with some sensor cysteine
residues of Keap1 (Fig. 10). We speculate that 17-oxo-DHA-induced
modification of Cys151 or Cys273 leads to activation of Nrf2 by in-
hibiting Keap1 dependent ubiquitination of Nrf2. Alternatively, 17-oxo-
DHA may promote p62-mediated autophagic degradation of Keap1.
Thus, 17-oxo-DHA holds great promise for use in the management of
skin diseases characterized by persistent oxidative stress or inflamma-
tion.
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